Alok Khorana is an Oncology physician. OpenAlex indexes 596 publications with 35,228 citations (h-index 83); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
601 Elmwood Avenue
Rochester, NY 146420001
Telephone
585-275-5823Registry record last updated 30 Apr 2012.
Clinical trials
- Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis
Sponsor: Case Comprehensive Cancer Center
- GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer
Sponsor: University of Rochester
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202512 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- Alnylam Pharmaceuticals Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
36.1%Serotonin-3 Receptor Antagonist20.8%Ondansetron Hcl100%Part D≥13 patientsProton pump inhibitor15.3%Omeprazole100%Part D<11 patientsNervous system
29.2%Atypical Antipsychotic29.2%Olanzapine100%Part D<11 patientsBlood & clotting
18.1%Factor Xa inhibitor18.1%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2006–2010 per NIH RePORTER. The latest:
- Risk Factors for Venous Thromboembolism in Cancer Patients Receiving Chemotherapy
University of Rochester
FY2010$129,965K23CA120587 - Risk Factors for Venous Thromboembolism in Cancer Patients Receiving Chemotherapy
University of Rochester
FY2009$129,165K23CA120587 - Risk Factors for Venous Thromboembolism in Cancer Patients Receiving Chemotherapy
University of Rochester
FY2008$129,165K23CA120587
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”